Media coverage about Zogenix (NASDAQ:ZGNX) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zogenix earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.282765580739 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Analysts See $-0.74 EPS for Zogenix, Inc. (ZGNX); Electronic Arts (EA) Has 0.85 Sentiment (mtastar.com)
- Investor’s Alert (EPS in Focus) – Zogenix Inc (NASDAQ: ZGNX) (stocksmarketcap.com)
- Zogenix, Inc. (ZGNX) EPS Estimated At $-0.74; Great Lakes Advisors Lowered By $3.34 Million Its Palo Alto Networks … (mtastar.com)
- Global Needle Free Diabetes Management Market 2018 -Zogenix, JDRF, Akra Dermojet, 3M (marketingcorrect.com)
- Zogenix, Inc. (ZGNX): Intraday Healthcare Mover: (stocksgeeks.com)
Zogenix stock opened at $40.15 on Monday. The firm has a market cap of $1,370.10, a PE ratio of -9.99 and a beta of 1.68. Zogenix has a fifty-two week low of $10.05 and a fifty-two week high of $45.85.
Several analysts have issued reports on the stock. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. Mizuho reiterated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a research note on Wednesday, March 7th. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $53.20.
In other news, Director Roger Hawley sold 35,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 5.00% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.